RecruitingNCT05925621

Cognitive Neurology Unit Clinical Registry

Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry

Sponsor

Beth Israel Deaconess Medical Center

Enrollment

500 participants

Start Date

Jul 16, 2023

Study Type

OBSERVATIONAL

Conditions

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

Min Age: 50 YearsMax Age: 95 Years

o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease
Patient has evidence of cognitive impairment on neuropsychological testing
Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
Amyloid PET imaging positive
CSF p-Tau/Abeta42 ration \>0.023 and ABeta42 \< 1027\*\*
T MRI in past 6 months
Patient has a care partner
Patient under the care of an appropriate BI-Lahey amyloid clinic
Patient is on a stable medication regimen

o Recent stroke or suspected TIA in the past year
Pregnancy
Active autoimmune or immunological disease
Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
Bleeding disorder with Plts \< 50,000 or INR \> 1.5
On warfarin, heparin, or DOAC
On dual antiplatelet therapy
Non Alzheimer disease cause of dementia/MCI
ApoE e4 homozygote